Pravin U. Dugel, MD: Opthea Meets Primary Endpoint in Phase 2b Study of OPT-302 in Wet AMD
OPT-302 Combination Therapy Demonstrated Superiority in Visual Acuity over Lucentis®
|
|
|
OPT-302 Combination Therapy Demonstrated Superiority in Visual Acuity over Lucentis®
|
|
|